데라콕시브

비스테로이드성 항염증제 (NSAID) - 콕시브계

데라콕시브(Deracoxib)는 수의학용으로 특별히 제조된 **콕시브계 비스테로이드성 항염증제(NSAID)**입니다. 반려견의 **골관절염**과 관련된 통증 및 염증 관리, 그리고 **수술 후 통증** 관리에 대해 FDA 승인을 받았습니다. * **임상 요점**: 피록시캄과 마찬가지로, 방광의 이행세포암종(TCC)에서 COX-2가 과발현되기 때문에 데라콕시브는 보조 치료제로서의 잠재력을 보여줍니다. * 기호성이 높은 츄어블 정제이므로 투약 순응도를 높이지만, 우발적인 과다 복용의 위험도 증가시키므로 보관에 주의해야 합니다.

작용 기전: Deracoxib is a **selective COX-2 inhibitor** (coxib). * **Arachidonic Acid Cascade**: It inhibits the **cyclooxygenase-2 (COX-2)** enzyme → decreases the synthesis of pro-inflammatory **prostaglandins** (e.g., PGE2) responsible for pain, inflammation, and fever. * At therapeutic doses, it largely spares **COX-1**, the constitutive enzyme responsible for maintaining normal gastrointestinal mucosal integrity, renal blood flow, and platelet function. * *Note*: COX-2 selectivity is dose-dependent. At higher doses, COX-1 inhibition occurs, increasing the risk of gastrointestinal and renal toxicity.

동물 종별 용량

Dogs

Control of pain and inflammation associated with osteoarthritis · 1-2 mg/kg PO once a day as needed · PO · q24h · Ongoing
Treatment of post-operative pain · 3-4 mg/kg PO once a day as needed · PO · q24h · Not to exceed 7 days of therapy at this dosage

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

Known hypersensitivity to deracoxib

이상반응

Vomiting
Anorexia/weight loss
Diarrhea
Melena
Hematemesis
Hematochezia
GI ulceration/perforation
Azotemia
Polydipsia/polyuria
Urinary tract infection (UTI)
Hematuria
Urinary incontinence
Renal failure
Anemia
Thrombocytopenia
Elevated hepatic enzymes
Changes in total protein

약물 상호작용

ACE Inhibitors (e.g., enalapril, benazepril) · NSAIDs can reduce effects on blood pressure. Concurrent use may increase the risk for renal injury due to reduced renal blood flow.
Aspirin · May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). A multi-day washout period is warranted when switching.
Corticosteroids (e.g., prednisone) · May significantly increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea).
Digoxin · NSAIDs may increase serum levels of digoxin.
Fluconazole · May increase plasma levels of deracoxib (extrapolated from human celecoxib data).
Furosemide · NSAIDs may reduce saluretic and diuretic effects.
Methotrexate · Serious toxicity has occurred when NSAIDs are used concomitantly; use with extreme caution.
Nephrotoxic Drugs (e.g., aminoglycosides, amphotericin B) · May enhance the risk of developing nephrotoxicity.
Other NSAIDs · May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea).

모니터링

Baseline and periodic CBC and serum chemistry (including BUN/serum creatinine, and liver function assessment)
Baseline history and physical
Efficacy of therapy
Adverse effect monitoring via client

과용량

Acute toxicity data indicates non-linear elimination occurs in dogs at dosages of 10 mg/kg and above. * **10 mg/kg/day**: No clinically observable adverse effects in a 14-day study, though focal tubular necrosis was seen in 3 of 10 dogs in a 6-month safety study. * **25-100 mg/kg/day**: Dogs survived 10-11 days but showed vomiting and melena. * **Clinical Signs of Overdose**: Vomiting, diarrhea, lethargy, and elevated creatinine. > **Treatment**: Decontamination with emetics and/or activated charcoal is appropriate for acute ingestions. The ASPCA APCC recommends **GI protectants** at acute dosages of 15 mg/kg and above, and **IV fluid diuresis** at dosages of 30 mg/kg and above in healthy dogs. Monitor for GI erosion/ulceration and treat symptomatically.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.